Comparing Neoadjuvant Nab-paclitaxel Vs Paclitaxel Both Followed by Anthracycline Regimens in Women with ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment with Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial